Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.
Infectious DiseasesOncology
Technology Platform
Prime/Boost System of Vaccines (PBS Vax™) platform that enables quantitative and qualitative 'tuning' of immune responses (humoral or cellular) to specific pathogen targets for both preventive and therapeutic applications.
Funding History
5
Total raised:$17.4M
Seed$10MUndisclosed
Grant$1.0MNIAID
Grant$4.1MNIAID
Grant$1.2MNIAID
Opportunities
Significant opportunities exist in advancing its proprietary pipeline (HPV, RSV, Chikungunya) into clinical proof-of-concept, which could attract partnership or further investment.
The company is also well-positioned to secure additional government and NGO funding for its biodefense and pandemic preparedness programs, leveraging its established track record with CEPI and the NIH.
Risk Factors
Key risks include clinical failure of its novel platform technology, intense competition from large pharma in core indications like RSV, and dependency on the execution capabilities of its licensees and partners for major programs.
As a subsidiary, strategic direction is also subject to parent company priorities.
Competitive Landscape
Auro Vaccines faces competition from large pharmaceutical companies (GSK, Pfizer, Moderna, J&J) with substantial resources and approved products, particularly in RSV and pandemic response. Its differentiation hinges on the claimed precision and tunability of its PBS Vax™ platform to generate optimized immune responses, a feature it must demonstrate clinically to gain a competitive edge.
